XHKG2137
Market cap95mUSD
Dec 30, Last price
1.01HKD
1D
1.00%
1Q
-20.47%
IPO
-95.41%
Name
Brii Biosciences Ltd
Chart & Performance
P/E
—
P/S
12.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
56m
+9.10%
Net income
-175m
L-61.37%
CFO
-594m
L+19.69%
Earnings
Mar 20, 2025
Profile
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 56,322 9.10% | 51,626 -44.21% | |||
Cost of revenue | 459,809 | 520,960 | |||
Unusual Expense (Income) | |||||
NOPBT | (403,487) | (469,334) | |||
NOPBT Margin | |||||
Operating Taxes | (37,155) | ||||
Tax Rate | |||||
NOPAT | (403,487) | (432,179) | |||
Net income | (174,829) -61.37% | (452,626) -89.01% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (983) | 6,769 | |||
BB yield | 0.06% | -0.13% | |||
| Debt | |||||
Debt current | 3,156 | 9,500 | |||
Long-term debt | 3,156 | 15,812 | |||
Deferred revenue | 2,083 | ||||
Other long-term liabilities | 2,083 | ||||
Net debt | (625,782) | (1,311,288) | |||
| Cash flow | |||||
Cash from operating activities | (594,014) | (496,279) | |||
CAPEX | (139,292) | ||||
Cash from investing activities | (104,350) | (1,433,168) | |||
Cash from financing activities | (10,977) | (3,042) | |||
FCF | (390,989) | (418,266) | |||
| Balance | |||||
Cash | 2,660,661 | 2,997,384 | |||
Long term investments | (2,028,567) | (1,660,784) | |||
Excess cash | 629,278 | 1,334,019 | |||
Stockholders' equity | (6,304,396) | (6,194,616) | |||
Invested Capital | 9,379,934 | 9,367,074 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 728,100 | 723,478 | |||
Price | 2.28 -69.06% | 7.37 -77.46% | |||
Market cap | 1,660,068 -68.87% | 5,332,033 -62.86% | |||
EV | 987,628 | 3,983,628 | |||
EBITDA | (387,813) | (452,302) | |||
EV/EBITDA | |||||
Interest | 494 | 851 | |||
Interest/NOPBT | |||||